1 A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in
Several Cohort and Case/Control Sets. Chiara Herzog et. al.. Journal of Clinical Oncology 2022. DOI: 10.1200/JCO.22.00266
2 The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers. Lena
Schreiberhuber, Chiara Herzog et. al.. International Journal of Cancer 2022. DOI: 10.1002/ijc.34275
Tyrolpath Obrist Brunhuber GmbH
Hauptplatz 4
6511 Zams
Mail office@tyrolpath.at
Tel +43 5442/66611
Fax +43 5442/66611-11
WID®-easy Test
✓ Nicht-invasiver hochgenauer Test auf
Endometriumkarzinom 1
✓ Sensitivität 97-100 % 1,2
✓ Spezifität 76-89 % 2
✓ NPV 99 % 1

1 A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in
Several Cohort and Case/Control Sets. Chiara Herzog et. al.. Journal of Clinical Oncology 2022. DOI: 10.1200/JCO.22.00266
2 The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers. Lena
Schreiberhuber, Chiara Herzog et. al.. International Journal of Cancer 2022. DOI: 10.1002/ijc.34275
Tyrolpath Obrist Brunhuber GmbH
Hauptplatz 4
6511 Zams
Mail office@tyrolpath.at
Tel +43 5442/66611
Fax +43 5442/66611-11
WID®-easy Test
✓ Einfache Probennahme mittels zervikovaginalem
Abstrich (ThinPrep®)
✓ Schnelle Befundung ermöglicht schnelle Diagnosestellung
✓ Erkennt auch Zervixkarzinome 2
✓ Hohe Spezifität vermindert die Anzahl notwendiger invasiver Eingriffe 1,2
✓ Hohe Sensitivität und Objektivität der Messung geben zusätzliche Sicherheit
beim Ausschluss einer Krebserkrankung

WID®-easy Test
Der Test wird empfohlen bei Verdacht auf
Endometrium- oder Zervixkarzinom, z.B. bei
✓ Post- oder Perimenopausalen abnormen Blutungen
✓ Prämenopausalen Blutungen, bei Vorliegen zusätzlicher Risikofaktoren wie beispielsweise
๏ Lynchsyndrom
๏ BMI > 30
๏ Polyzystisches Ovarialsyndrom
✓ Hyperplasien und sonographische Auffälligkeiten
1 A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in
Several Cohort and Case/Control Sets. Chiara Herzog et. al.. Journal of Clinical Oncology 2022. DOI: 10.1200/JCO.22.00266
2 The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers. Lena
Schreiberhuber, Chiara Herzog et. al.. International Journal of Cancer 2022. DOI: 10.1002/ijc.34275
Tyrolpath Obrist Brunhuber GmbH
Hauptplatz 4
6511 Zams
Mail office@tyrolpath.at
Tel +43 5442/66611
Fax +43 5442/66611-11

1 A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in
Several Cohort and Case/Control Sets. Chiara Herzog et. al.. Journal of Clinical Oncology 2022. DOI: 10.1200/JCO.22.00266
2 The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers. Lena
Schreiberhuber, Chiara Herzog et. al.. International Journal of Cancer 2022. DOI: 10.1002/ijc.34275
Tyrolpath Obrist Brunhuber GmbH
Hauptplatz 4
6511 Zams
Mail office@tyrolpath.at
Tel +43 5442/66611
Fax +43 5442/66611-11
WID®-easy Test
Verfügbar ab
November 2022
Weitere Informationen bei
Tyrolpath Obrist Brunhuber GmbH
Email office@tyrolpath.at
Tel +43 5442/66611